"L\u00E9\u010Dba selh\u00E1n\u00ED ledvin u mnoho\u010Detn\u00E9ho myelomu" . . . "4"^^ . . . "6" . "H\u00E1jek, Roman" . "L\u00E9\u010Dba selh\u00E1n\u00ED ledvin u mnoho\u010Detn\u00E9ho myelomu"@cs . . "[5D0401F22158]" . "55" . . . "13"^^ . . . "The treatment of renal failure in multiple myeloma"@en . "6"^^ . "P(LC06027), R, Z(MSM0021622434)" . . "Pour, L." . "multiple myeloma; light chain deposition disease"@en . . . "0042-773X" . "Krej\u010D\u00ED, Marta" . . . . "323467" . . "L\u00E9\u010Dba selh\u00E1n\u00ED ledvin u mnoho\u010Detn\u00E9ho myelomu" . "CZ - \u010Cesk\u00E1 republika" . . . "RIV/65269705:_____/09:#0000736" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "The treatment of renal failure in multiple myeloma"@en . "Adam, Zden\u011Bk" . "L\u00E9\u010Dba pacient\u016F s mnoho\u010Detn\u00FDm myelomem se selh\u00E1vaj\u00EDc\u00EDmi ledvinami je komplikov\u00E1na zv\u00FD\u0161enou \u010Dasnou mortalitou, kter\u00E1 dosahuje v prvn\u00EDch 3 m\u011Bs\u00EDc\u00EDch a\u017E 30%. \u010C\u00EDm t\u011B\u017E\u0161\u00ED je po\u0161kozen\u00ED ledvin monoklon\u00E1ln\u00EDm imunoglobulinem, t\u00EDm m\u00E9n\u011B pravd\u011Bpodobn\u00E1 je \u00FAprava funkce ledvin p\u0159i l\u00E9\u010Db\u011B. pro osud nemocn\u00E9ho je extr\u00E9mn\u011B d\u016Fle\u017Eit\u00E9, zda je tato nemoc diagnostikov\u00E1na v\u010Das, v dob\u011B, kdy je je\u0161t\u011B po\u0161kozen\u00ED ledvin reverzibiln\u00ED. Z\u00E1kladem l\u00E9\u010Dby jsou l\u00E9\u010Debn\u00E9 re\u017Eimy obsahuj\u00EDc\u00ED vysok\u00E9 d\u00E1vky glukokortikoid\u016F. kombinace nov\u00FDch vysoce \u00FA\u010Dinn\u00FDch l\u00E9k\u016F (bortezomibu nebo thalidomidu) s vysok\u00FDmi d\u00E1vkami glukokortikoid\u016F a s alkyla\u010Dn\u00EDm cytostatikem nebo s doxorubicinem maj\u00ED nejrychlej\u0161\u00ED n\u00E1stup \u00FA\u010Dinku, a tedy nejvy\u0161\u0161\u00ED pravd\u011Bpodobnost, aby hematologickou l\u00E9\u010Debnou odpov\u011B\u010F n\u00E1sledovalo zlep\u0161en\u00ED funkce ledvin. U pacient\u016F s p\u0159etrv\u00E1vaj\u00EDc\u00EDm ren\u00E1ln\u00EDm selh\u00E1n\u00EDm se doporu\u010Duje vysokod\u00E1vkovan\u00E1 chemoterapie, p\u0159edev\u0161\u00EDm pro podskupinu nemocn\u00FDch s chemosenzitivn\u00EDm onemocn\u011Bn\u00EDm, d\u00E1vka melfalanu by nem\u011Bla p\u0159ekro\u010Dit 140 mg/m2."@cs . "L\u00E9\u010Dba selh\u00E1n\u00ED ledvin u mnoho\u010Detn\u00E9ho myelomu"@cs . "Elevated early mortality reaches 30% during the first 3 months and complicates treatment of patients with multiple myeloma with renal failure. More serious the renal damage caused by monoclonal immunoglobulin is, less likely is the improvement of renal function following treatment. Early diagnosis at the time when renal impairment is still reversible is extremely important for the patient\u00B4s prognosis. Treatment regimenswith high-dose glucocorticoids form the basis of treatment. Combined treatments with new, higly effective drugs (bortezomib or thalidomide) with high-dose glucocorticoids and an alkylating cytostatic agent, or with doxorubicin, have the fastest onset of action and thus provide the highest likelihood that haematological treatment response will be followed by improved renal function. High-dose chemotherapy is recommended in patients with persisting renal failure, particularly in the subgroup of patients with chemotherapy-sensitive disease; melphalan dose should not exceed 140 mg/m2."@en . . . "RIV/65269705:_____/09:#0000736!RIV10-MZ0-65269705" . "L\u00E9\u010Dba pacient\u016F s mnoho\u010Detn\u00FDm myelomem se selh\u00E1vaj\u00EDc\u00EDmi ledvinami je komplikov\u00E1na zv\u00FD\u0161enou \u010Dasnou mortalitou, kter\u00E1 dosahuje v prvn\u00EDch 3 m\u011Bs\u00EDc\u00EDch a\u017E 30%. \u010C\u00EDm t\u011B\u017E\u0161\u00ED je po\u0161kozen\u00ED ledvin monoklon\u00E1ln\u00EDm imunoglobulinem, t\u00EDm m\u00E9n\u011B pravd\u011Bpodobn\u00E1 je \u00FAprava funkce ledvin p\u0159i l\u00E9\u010Db\u011B. pro osud nemocn\u00E9ho je extr\u00E9mn\u011B d\u016Fle\u017Eit\u00E9, zda je tato nemoc diagnostikov\u00E1na v\u010Das, v dob\u011B, kdy je je\u0161t\u011B po\u0161kozen\u00ED ledvin reverzibiln\u00ED. Z\u00E1kladem l\u00E9\u010Dby jsou l\u00E9\u010Debn\u00E9 re\u017Eimy obsahuj\u00EDc\u00ED vysok\u00E9 d\u00E1vky glukokortikoid\u016F. kombinace nov\u00FDch vysoce \u00FA\u010Dinn\u00FDch l\u00E9k\u016F (bortezomibu nebo thalidomidu) s vysok\u00FDmi d\u00E1vkami glukokortikoid\u016F a s alkyla\u010Dn\u00EDm cytostatikem nebo s doxorubicinem maj\u00ED nejrychlej\u0161\u00ED n\u00E1stup \u00FA\u010Dinku, a tedy nejvy\u0161\u0161\u00ED pravd\u011Bpodobnost, aby hematologickou l\u00E9\u010Debnou odpov\u011B\u010F n\u00E1sledovalo zlep\u0161en\u00ED funkce ledvin. U pacient\u016F s p\u0159etrv\u00E1vaj\u00EDc\u00EDm ren\u00E1ln\u00EDm selh\u00E1n\u00EDm se doporu\u010Duje vysokod\u00E1vkovan\u00E1 chemoterapie, p\u0159edev\u0161\u00EDm pro podskupinu nemocn\u00FDch s chemosenzitivn\u00EDm onemocn\u011Bn\u00EDm, d\u00E1vka melfalanu by nem\u011Bla p\u0159ekro\u010Dit 140 mg/m2." .